Details

Autor(en) / Beteiligte

• Nelke, Christopher
• Schroeter, Christina B.
• Pawlitzki, Marc
• Meuth, Sven G.
• Ruck, Tobias

Titel

Cellular senescence in neuroinflammatory disease: new therapies for old cells?

Ist Teil von

• Trends in molecular medicine, 2022-10, Vol.28 (10), p.850-863

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Neuroinflammatory diseases remain a therapeutic challenge, notably when progressing towards neurodegeneration. In this context, multiple sclerosis represents a central nervous system (CNS) disorder that combines pathogenic inflammatory and degenerative processes. Immunosuppression is effective for managing inflammatory activity, but neurodegenerative processes secondary to chronic inflammation are often refractory to contemporary treatments. Recent evidence indicates that pathways involved in chronic neuroinflammation demonstrate features of cellular senescence. These features could provide a framework that could serve as a target for senotherapeutics. In this review, we discuss the unmet need for strategies capable of overcoming the treatment resistance of neuroinflammatory diseases, and we discuss the potential of cellular senescence towards developing these strategies. There is an unmet need for novel therapeutic strategies that can halt neuroinflammatory disorders progressing towards a degenerative phenotype.Accumulating evidence links cellular senescence to a plethora of human diseases.Initial data indicate the presence of cellular senescence in neuroinflammatory disorders, suggesting it as a potential driver of pathogenesis.Senotherapeutics were able to reduce the senescent burden in animal models and, more recently, in humans.Incorporating senotherapeutics in the field of neuroinflammation could improve treatment outcomes.